Progression of Late-Onset Stargardt Disease

Stanley Lambertus,1 Moritz Lindner,2 Nathalie M. Bax,1 Matthias M. Mauschitz,2 Jennifer Nadal,3 Matthias Schmid,3 Steffen Schmitz-Valckenberg,2 Anneke I. den Hollander,1,4 Bernhard H. F. Weber,5 Frank G. Holz,2 Gert Jan van der Wilt,6 Monika Fleckenstein,2 and Carel B. Hoyng1; for the Foveal sparing Atrophy Study Team (FAST)

1Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
2Department of Ophthalmology, University of Bonn, Bonn, Germany
3Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany
4Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
5Institute of Human Genetics, University of Regensburg, Regensburg, Germany
6Department for Health Evidence, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

Correspondence: Carel B. Hoyng, Department of Ophthalmology, Radboud University Medical Center, P.O. Box 9101 (OHK400), 6500 HB Nijmegen, The Netherlands; carel.hoyng@radboudumc.nl.

SL and ML are joint first authors.

MF and CBH contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Submitted: April 28, 2016
Accepted: August 5, 2016
Citation: Lambertus S, Lindner M, Bax NM, et al.; for the Foveal sparing Atrophy Study Team (FAST). Progression of late-onset Stargardt disease. Invest Ophthalmol Vis Sci. 2016;57:5186–5191. DOI:10.1167/iovs.16-19833

PURPOSE. Identification of sensitive biomarkers is essential to determine potential effects of emerging therapeutic trials for Stargardt disease. This study aimed to describe the natural history of late-onset Stargardt, and demonstrates the accuracy of retinal pigment epithelium (RPE) atrophy progression as an outcome measure.

METHODS. We performed a retrospective cohort study collecting multicenter data from 47 patients (91 eyes) with late-onset Stargardt, defined by clinical phenotype, at least one ABCA4 mutation, and age at disease onset ≥ 45 years. We analyzed RPE atrophy progression on fundus autofluorescence and near-infrared reflectance imaging using semiautomated software and a linear mixed model. We performed sample size calculations to assess the power in a simulated 2-year interventional study and assessed visual endpoints using time-to-event analysis.

RESULTS. Over time, progression of RPE atrophy was observed (mean: 0.22 mm/year, 95% confidence interval [CI]: 0.19–0.27). By including only patients with bilateral RPE atrophy in a future trial, 32 patients are needed to reach a power of 83.9% (95% CI: 83.1–84.6), assuming a fixed therapeutic effect size of 30%. We found a median interval between disease onset and visual acuity decline to 20/32, 20/80, and 20/200 of 2.74 (95% CI: 0.54–4.41), 10.15 (95% CI: 6.13–11.38), and 11.38 (95% CI: 6.13–13.34) years, respectively.

CONCLUSIONS. We show that RPE atrophy represents a robust biomarker to monitor disease progression in future therapeutic trials. In contrast, the variability in terms of the course of visual acuity was high.

Keywords: late-onset Stargardt, fundus autofluorescence, retinal pigment epithelium atrophy, biomarker, disease progression

Stargardt disease is an autosomal recessive retinal dystrophy caused by mutations in the ABCA4 gene, and affects 1:8000 to 1:10,000 people worldwide.1 Patients generally develop central loss of vision in childhood or early adulthood.2–4 However, late-onset Stargardt can be diagnosed at age ≥ 45 years, and has been associated with carrying one or two mutant ABCA4 alleles.5,6 Patients with this late-onset variant may first present with metamorphopsia or oscillopsia without any decrease in visual acuity. Occasionally, these patients are asymptomatic and are coincidentally diagnosed during screening tests for other retinal diseases, such as glaucoma, diabetes or thyroid disease.

The natural course of late-onset Stargardt includes a typical phenotype of yellow-white flecks and retinal pigment epithelium (RPE) atrophy. Patchy atrophy initially occur in the parafoveal retina and radially expand in size over time. New atrophic areas can arise; multifocal atrophic areas coalesce. Atrophic areas can form a ring encircling the intact and still-functioning fovea. Then, it is only until late in the disease course that the fovea will be involved in the atrophic process.7–9 The patient’s fixation point eventually shifts eccentrically, which leads to a substantial loss of visual acuity.10 However, central atrophy can also develop early in the disease course, and only minor disease progression has been described in other patients.5 Indeed, substantial variations in RPE atrophy progression have been reported before in small groups of typical Stargardt patients.11 Yet analyses of the natural course of large late-onset Stargardt cohorts are missing.

In light of recently upcoming therapeutic options for Stargardt disease,12–14 accurate biomarkers to determine their potential effects are crucial. The well-defined area of RPE atrophy is a frequent feature of late-onset Stargardt, showing
similarities to geographic atrophy in age-related macular degeneration (AMD). Fundus autofluorescence (FAF) imaging can clearly visualize such areas of RPE atrophy,15,16 and change in RPE atrophy over time by FAF has already been accepted as a clinical endpoint by the U.S. Food and Drug Administration in AMD.17 We hypothesize that areas of RPE atrophy could also serve to sensitively monitor the effect of a drug trial in late-onset Stargardt. This would make patients with late-onset Stargardt appropriate candidates for upcoming therapeutic trials. In this study, we describe the natural history in late-onset Stargardt patients, and identify cohorts based on imaging parameters that determine the visual course in these patients. We quantify atrophy progression with semiautomated software, previously validated for AMD,18 showing the accuracy of this outcome measure, and include sample size calculations that are valuable for the design of upcoming therapeutic trials.

**METHODS**

**Patient Selection**

We identified patients from the Stargardt database of the Department of Ophthalmology at Radboud University Medical Center (Nijmegen, The Netherlands) and from the participants in the prospective natural history study Fundus Autofluorescence in Age-related Macular Degeneration (FAM; NCT003959692).

We included 47 patients with a late disease onset, defined by an age ≥ 45 years at which symptoms were first noticed.5 If the patient did not report any symptoms, we used the age at which the patient was diagnosed by an ophthalmologist. We clinically considered patients to have late-onset Stargardt when typical yellow-white flecks or dots were seen that correlated with hyperautofluorescent flecks on 488-nm FAF imaging.

Patients were analyzed for the presence of mutations in the ATP-binding cassette, subfamily A, member 4 (ABCA4, NM_000350.2) gene. Clinical diagnosis was confirmed by genetic testing if at least one ABCA4 mutation was found. We excluded patients without evidence of ABCA4 mutations. In patients carrying only one ABCA4 mutation, we performed additional sequencing of the peripherin-2 gene (PRPH2, NM_000322.4) to exclude pseudo-Stargardt pattern dystrophy and central areolar choroidal dystrophy.19,20

This cohort study was carried out with approval from the Institutional Ethics Committee at Radboud University Medical Center (Nijmegen, The Netherlands) and the University Hospital of Bonn (Bonn, Germany), and adhered to the tenets of the Declaration of Helsinki. All patients provided informed consent before giving a blood sample and receiving additional ophthalmologic examinations to complete the clinical assessment.

**Clinical Assessment**

We reviewed the patients’ records for ophthalmologic history and available technical examinations, including sex, age at disease onset, and age at baseline. Best-corrected visual acuity (BCVA) was measured using a Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) chart, then transformed into the logarithm of the minimum angle of resolution (logMAR) for subsequent analysis. Fundus characteristics were documented using fundus photography (Topcon TRC-50IX; Topcon Corporation, Tokyo, Japan; or Visucam 500; Carl Zeiss Meditec, Jena, Germany). Fundus autofluorescence (λ = 488 nm; emission 500–700 nm) and near-infrared reflectance (NIR; λ = 820 nm) imaging were performed using a confocal scanning laser ophthalmoscope (Spectralis HRA+OCT or HRA2; Heidelberg Engineering, Heidelberg, Germany) in a subset of visits. The field of view was set at 30° × 30° or 55° × 55° and was centered on the macula. Eyes with signs of choroidal neovascularization were excluded from further analysis.

**Image Grading and Cohorts**

For each visit, two independent graders (MF and ML), blinded to each other’s results, evaluated the status of the fovea and the presence of clearly demarcated RPE atrophy (analogous to “definitely decreased autofluorescence,” the term recently used by Kuehlewein et al.21) on all available imaging modalities. Atrophy was graded as follows: (1) no RPE atrophy with an intact fovea, (2) extrafoveal (but not fovea encircling) RPE atrophy, (3) a typical “foveal sparing” phenotype in which RPE atrophy encircled the fovea by ≥180°,20 or (4) foveal involvement. Foveal involvement was indicated by a mottled or absent autofluorescent signal (equaling what was ultimately termed “well/poorly demarcated questionably decreased autofluorescence”).21 In cases of discrepancy, a third grader (SL) evaluated the images. His agreement with one of the independent graders was finally used. Based on this grading, eyes were exploratively analyzed in order to form cohorts that might be predictive for visual acuity loss.

**Quantitative Measurements of Retinal Pigment Epithelium Atrophy**

Two independent graders (MF and ML), blinded to each other’s results, performed measurements of the area of RPE atrophy using the RegionFinder software (version 2.5.5.0, Heidelberg Engineering) on FAF images, as previously established for AMD.18 In cases in which the foveal borders of the atrophy could not be well determined in FAF images, NIR images were included in the analysis wherever available.22 The final value was defined as the average of the two measurements between the readers, provided that the two measurements did not differ by >0.15 mm². If the difference exceeded 0.15 mm², a senior reader (MMM) additionally performed the measurement.18 We calculated the final value by averaging the senior reader measurement along with the closer of the two other reader measurements.

**Statistical Analysis**

We analyzed data using SAS Statistical Analysis Software Version 9.2 (SAS Institute, Cary, NC, USA) and R Version 3.1.2.23 Supplementary Figure S1 gives an overview of the analytical process applied in this work. Changes in visual acuity over time were assessed by time-to-event curves (cumulative distribution functions), and atrophy progression was analyzed using linear mixed-effects models. We performed a simulation study for power calculation for possible future interventional trials. Unless otherwise stated, all values given in the text represent median, minimum, and maximum values. Groups were compared by Mann–Whitney U tests. Details on the statistical procedures can be found in Supplementary Text S1.

**RESULTS**

**Patient Features and Initial Symptoms**

A total of 91 eyes of 47 patients (19 men, 28 women) were included in this study. Two mutations in the ABCA4 gene were found in 20 patients (42.6%) and one mutation in 27 (57.4%; Supplementary Table S1). The median age at disease onset was
54 years (range, 45–84). Self-reported initial symptoms were obtained for 42 patients and included a decrease in visual acuity (n = 24; 50%), metamorphopsia (n = 12; 29%), nyctalopia (n = 5; 12%), paracentral scotomas (n = 4; 10%), or oscillopsia (n = 1; 2%). Twelve patients (29%) did not report any visual complaints. In five patients, initial symptoms were not unequivocally denoted in the patient’s file.

Course of Visual Acuity
Overall, visual acuity data were available from 632 eye visits. At the first presentation after disease onset, the median disease duration was 0.9 years (range, 0–25.6) with a median BCVA of 0.10 logMAR (range, −0.14 to 1.70; Snellen 20/25). The median follow-up time of the patients with more than a single visit (45 out of 47 patients) was 4.8 years (range, 0.04–25.0). Time-to-event analysis yielded a median and 95% confidence interval (CI) between the age at onset and a decline in BCVA to mild visual impairment (n = 62), moderate visual impairment (n = 39), and severe visual impairment (n = 35) of 2.74 (0.54–4.41), 10.15 (6.13–11.38), and 11.38 (9.34–13.34) years, respectively (Fig. 1). The median disease duration at the final visit was 6.8 years (range, 0–30.9). The median BCVA at the final visit was 0.37 logMAR (range, −0.10 to 1.80; Snellen 20/47).

Assessment of Retinal Features
For each patient, clinical imaging data were available for a subset of visits (241 eye visits of 91 eyes). At baseline (first visit with imaging data available), yellow-white flecks were observed in all but one patient, in whom small yellowish spots were noted. An apparently intact fovea (Fig. 2A) without mottled or sharply decreased autofluorescence indicating RPE atrophy was present in 58 eyes. Out of these 58 eyes without foveal involvement, 22 had no RPE atrophy (Fig. 2B), 16 had extrafoveal (but not fovea encircling) atrophy (Fig. 2C), and 20
had a foveal sparing pattern of RPE atrophy encircling the fovea \(\geq 180^\circ\) (Fig. 2D). The other 32 eyes had an involved fovea by either a mottled appearance (23 eyes; Fig. 2E) or central RPE atrophy (9 eyes; Fig. 2F). One eye was excluded because it was inconclusive if the fovea appeared mottled. There was no significant difference in patient’s age between eyes that initially had foveal involvement and those that did not (median: 60.4 \(\pm\) 32 and 61.0 years \(\pm\) 61.0). Eyes in cohorts I, II, III, and IV had a median disease duration of 3.4 years (range, 0–11.7), 3.3 (range, 0.1–11.7), 8.7 (range, 2.1–30.9), and 11.4 (range, 0.3–30.9) years, respectively. Eyes in cohorts I and II had a median visual acuity of 0.10 (–0.20 to 0.64) and 0.05 (–0.10 to 0.72), respectively. The median visual acuity at the last visit; cohort III developed foveal sparing (RPE atrophy encircling the fovea \(\geq 180^\circ\)); and cohort IV had foveal involvement by either a mottled fovea or central RPE atrophy without passing through a foveal sparing phenotype during the observational interval.

### Cohorts

Assessment of retinal features over the entire imaging interval (Table 1) enabled us to categorize the eyes into four clearly distinctive cohorts. During the entire follow-up period, 20 eyes (22.2%) showed only flecks without any mottled foveal alterations or RPE atrophy (cohort I). Eleven eyes (12.2%) showed extrafoveal but not foveal encircling RPE atrophy (cohort II). Twenty-six eyes (28.2%) developed foveal sparing (RPE atrophy encircling the fovea \(\geq 180^\circ\); cohort III). In four of these 26 eyes, the fovea eventually involved in the atrophic process at the last visit. Thirty-three eyes (36.7%) showed central RPE and revealed that atrophy progression rates moderately correlated between the two eyes of a single patient (Pearson’s \(r = 0.52\); Supplementary Fig. S3). At the first visit, the mean RPE atrophy size was 6.26 mm\(^2\) (\(\pm\) standard deviation: 7.3).

**Modeling of Retinal Pigment Epithelium Atrophy**

We assessed changes in RPE atrophy area over time in a subset of visits from 66 eyes (from 21 female and 17 male patients). The median follow-up time with FAF imaging was 2.3 years (range, 0.07–7.7). Measurement of RPE atrophy size was possible with high agreement between two independent readers (Supplementary Fig. S2). At the first visit, the mean RPE atrophy size was 6.26 mm\(^2\) (\(\pm\) standard deviation: 7.3). Square root transformed data were used for all further analysis. Modeling RPE atrophy over time revealed an annual atrophy progression rate (slope) of 0.22 mm/year (95% CI: 0.19–0.27). Square root transformed data were used for all further analysis. Modeling RPE atrophy over time revealed an annual atrophy progression rate (slope) of 0.22 mm/year (95% CI: 0.19–0.27).

For 28 patients, data on RPE atrophy progression were available from both eyes for the same observational interval, and revealed that atrophy progression rates moderately correlated between the two eyes of a single patient (Pearson’s \(r = 0.52\); Supplementary Fig. S3).

**Table 2.** Median Times (Years; 95% Confidence Interval) of Best-Corrected Visual Acuity Decline Since the Age at Onset Compared Between Eyes of Late-Onset Stargardt Patients Who Developed Foveal Sparing and Those Who Had Early Foveal Involvement

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Mild Impairment ((\leq 20/32, \geq 0.2) logMAR)</th>
<th>Moderate Impairment ((\leq 20/80, \geq 0.6) logMAR)</th>
<th>Severe Impairment ((\leq 20/200, \geq 1.0) logMAR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foveal sparing, cohort III</td>
<td>0.95 (NA(^*-6.61)) years</td>
<td>10.15 (3.09–13.34) years</td>
<td>23.3 (13.6–NA(^*))</td>
</tr>
<tr>
<td>Foveal involvement, cohort IV</td>
<td>0.51 (NA(^*-4.41)) years</td>
<td>7.73 (4.30–22.89) years</td>
<td>NA(^<em>) (24.0–NA(^</em>))</td>
</tr>
<tr>
<td>Log-rank test</td>
<td>0.57</td>
<td>0.07</td>
<td>0.06</td>
</tr>
</tbody>
</table>

NA, not available.
* Values could not be calculated, as too many events occurred outside the observational interval.
Sample Size Calculations

Based on the observed progression kinetics and the agreement between two eyes of a single individual, we were able to perform sample size calculations for possible future therapeutic trials. The assumption of a trial duration of 2 years and inclusion of only patients with bilateral RPE atrophy resulted in the sample size–power relationship depicted in Figure 3, with expected effect sizes of 50%, 40%, and 30% reduction in RPE atrophy progression. For effect sizes of 50% and 40%, fewer than 25 patients would be needed to obtain a statistical power of 0.9 at the 5% significance level, while for an effect size of 30%, a power of 0.8 would be reached if at least 32 patients were included.

DISCUSSION

The natural history of late-onset Stargardt features expanding, well-demarcated areas of RPE atrophy, which can be a promising clinical biomarker to monitor disease progression. Although clinical features have been previously described,5 we comprehensively report on visual course and specific RPE atrophy progression rates in a large multicenter cohort that was well defined by clinical, genetic, and validated imaging parameters. In addition, we used advanced statistical methods to deliver robust results,24,25 as these are required for planning and conducting clinical trials. These measures ensured the highest levels of data integrity. As a result, this work showed that a future therapeutic trial can be realized with sufficient levels of data integrity. As a result, this work showed that a future therapeutic trial can be realized with sufficient levels of data integrity. As a result, this work showed that a future therapeutic trial can be realized with sufficient levels of data integrity. As a result, this work showed that a future therapeutic trial can be realized with sufficient levels of data integrity.
Progression of Late-Onset Stargardt

M. M. Mauschitz

M. Fleckenstein

References


7. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis. 1999;5:25.


